Japan Proton Therapy Market, Share, Forecast 2022-2027, Industry Trends, Growth, Size, Impact of COVID-19, Company Analysis
Japan Proton Therapy Market Potential will be US$ 8.6 Billion by 2027. Over the years, various techniques for cancer treatment have emerged, such as chemotherapy, surgery, and proton therapy. The proton therapy is the new technology and is expected to least impair the quality of life compared to other forms of treatment. Japan has one of the highest numbers of proton therapy treatment clinics globally. The improving cutting-edge technology in radiotherapy and growing technological development in Japan will further drive the Japan proton therapy industry in the future.
COVID-19 Impact on Japan Proton Therapy Industry
Despite the outbreak of COVID-19 worldwide, the proton therapy market has grown at a constant rate. Proton therapy’s radiation therapy was stopped for a brief round period, but it was resumed for patients. In addition, to take care of the regular patient and radiation therapies patients in Japan, many processes have been finalized to help the patients with therapies; as such many implementations and algorithms have been carried out to safeguard the radiation patients from COVID-19.
Japan Proton Therapy Potential Market Size was US$ 6.1 Billion post-pandemic recoveries in 2021
The growth of the proton therapy market in Japan is mainly driven by rising healthcare expenditure, expanding preference for advanced therapies by healthcare practitioners, increasing confirmation, and increasing cancer pervasiveness. Another outstanding growth driver is the faster uptake and access and premium pricing. As these systems become more widespread, they are likely to require further refinement and enhancement to respond to the needs of medical staff.
Cancer Types - Market Segmentation
Based on Cancer Types, the proton therapy market of Japan is further segmented into Central Nervous System (CNS) Tumors, Head and Neck Cancer, Lung Cancer, GI (Gastro-Intestinal) Cancer, Hepatocellular Carcinoma (HCC) Cancer, Pancreas Cancer, Gynecologic Cancers, Prostate Cancer, Bone, and Soft Tissue Cancer and Other Cancer. According to Renub Research report, Japan Proton Therapy Industry is expected to grow with a CAGR of 5.9% during 2021-2027.
Besides, proton therapy applications are more inclined towards Gastrointestinal Tract Cancer and lung cancer due to references by healthcare specialists. Moreover, proton therapy is also recognized to be comparatively safer in the case of patients with central nervous system (CNS) tumors.
Although there is less experience with proton therapy combined with chemotherapy for pancreatic cancer, favorable outcomes have been reported recently in Japan. Remarkably, these applications are anticipated to drive the revenue for the proton therapy industry over the forecast period.
Competitive Landscape
Companies existing in the Japan Proton Therapy Market are trying to create their mark by adopting new technologies at an accelerated rate. The company has also tried to enrich its product catalogs through product developments. Also, companies have acquired small companies to resolve the potential resource gap that prevailed in their technologies and products. The major players of the Japan Proton Therapy Market studied in our report are IBA Proton Therapy, Varian Medical Systems, and Elekta.
Renub Research report ""Japan Proton Therapy Market, Patients by 10 Cancer Types (Central Nervous System (CNS), Head and Neck, Lung, GI (Gastro-Intestinal), Hepatocellular Carcinoma (HCC), Pancreas, Gynecologic, Prostate, Bone and Soft Tissue, Others), Companies (IBA Proton Therapy, Varian Medical Systems, Elekta)"" Reimbursement Policies & Persons Treated at Centers provides a comprehensive assessment of the fast-evolving, high-growth of Japan Proton Therapy Market.
Cancer Types – Japan Proton Therapy Number of Patients have been covered from 10 viewpoints:
1. Central Nervous System (CNS) Tumors
2. Head and Neck Cancer
3. Lung Cancer
4. GI (Gastro-Intestinal) Cancer
5. Hepatocellular Carcinoma (HCC) Cancer
6. Pancreas Cancer
7. Gynecologic Cancers
8. Prostate Cancer
9. Bone and Soft Tissue Cancer
10. Others Cancer
Cancer Types – Japan Proton Therapy Market have been covered from 10 viewpoints:
1. Central Nervous System (CNS) Tumors
2. Head and Neck Cancer
3. Lung Cancer
4. GI (Gastro-Intestinal) Cancer
5. Hepatocellular Carcinoma (HCC) Cancer
6. Pancreas Cancer
7. Gynecologic Cancers
8. Prostate Cancer
9. Bone and Soft Tissue Cancer
10. Others Cancer
All companies have been covered from 3 viewpoints:
• Overview
• Recent Developments
• Sales Analysis
Companies Covered:
1. IBA Proton Therapy
2. Varian Medical Systems
3. Elekta
- 1. Introduction
- 2. Research & Methodology
- 3. Executive Summary
- 4. Market Dynamics
- 4.1 Growth Drivers
- 4.2 Challenges
- 5. Japan Proton Therapy Market (Actual & Untapped)
- 5.1 Actual Proton Therapy Market
- 5.2 Untapped Proton Therapy Market
- 6. Number of Patients – Japan Proton Therapy
- 6.1 Actual Numbers
- 6.2 Untapped Numbers
- 7. Cancer Types – Japan Proton Therapy Number of Patients
- 7.1 Central Nervous System (CNS) Tumors
- 7.2 Head and Neck Cancer
- 7.3 Lung Cancer
- 7.4 GI (Gastro-Intestinal) Cancer
- 7.5 Hepatocellular Carcinoma (HCC) Cancer
- 7.6 Pancreas Cancer
- 7.7 Gynecologic Cancers
- 7.8 Prostate Cancer
- 7.9 Bone and Soft Tissue Cancer
- 7.10 Others Cancer
- 8. Cancer Types – Japan Proton Therapy Market
- 8.1 Central Nervous System (CNS) Tumors
- 8.2 Head and Neck Cancer
- 8.3 Lung Cancer
- 8.4 GI (Gastro-Intestinal) Cancer
- 8.5 Hepatocellular Carcinoma (HCC) Cancer
- 8.6 Pancreas Cancer
- 8.7 Gynecologic Cancers
- 8.8 Prostate Cancer
- 8.9 Bone and Soft Tissue Cancer
- 8.10 Others Cancer
- 9. Japan – List of Proton Therapy Centers
- 9.1 Operating Proton Therapy Centers
- 9.2 Under-Construction Therapy Centers
- 10. Reimbursement Policies – Japan Proton Therapy
- 11. Components of a Standard Proton Therapy Center
- 11.1 Type of Proton Accelerator
- 11.1.1 Synchrotrons (example: LLUMC at Loma Linda)
- 11.1.2 Cyclotrons (example: MGH Boston)
- 11.1.3 Synchrocyclotrons (examples: Orsay, Uppsala)
- 11.1.4 Linacs (Rome)
- 11.1.5 H-minus Synchrotrons
- 11.1.6 Separated Sector Cyclotrons
- 11.1.7 Super-conducting Cyclotrons
- 11.1.8 Fast Cycling Synchrotron
- 11.2 Beam Transport System
- 11.3 Beam Delivery System
- 11.3.1 The Passive Scattering Technique
- 11.3.2 Beam Scanning
- 11.4 Type of Nozzle
- 11.4.1 Single Scattering
- 11.4.2 Double Scattering
- 11.4.3 Uniform Scanning Nozzle
- 11.4.4 Pencil Scanning Nozzle
- 11.5 Treatment Planning System
- 11.6 Image Viewers
- 11.7 Patient Positioning System (PPS)
- 11.8 Human Resource
- 12. Porters Five Forces
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
- 13. Company Analysis
- 13.1 IBA Proton Therapy
- 13.1.1 Overview
- 13.1.2 Recent Development
- 13.1.3 Sales Analysis
- 13.2 Varian Medical Systems
- 13.2.1 Overview
- 13.2.2 Recent Development
- 13.2.3 Sales Analysis
- 13.3 Elekta
- 13.3.1 Overview
- 13.3.2 Recent Development
- 13.3.3 Sales Analysis
- List Of Figures:
- Figure-01: Japan – Actual Proton Therapy Market (Million US$), 2016 – 2021
- Figure-02: Japan – Forecast for Actual Proton Therapy Market (Million US$), 2022 – 2027
- Figure-03: Japan – Untapped Proton Therapy Market (Million US$), 2016 – 2021
- Figure-04: Japan – Forecast for Untapped Proton Therapy Market (Million US$), 2022 – 2027
- Figure-05: Japan – Actual Numbers (Number), 2016 – 2021
- Figure-06: Japan – Forecast for Actual Numbers (Number), 2022 – 2027
- Figure-07: Japan – Untapped Numbers (Number), 2016 – 2021
- Figure-08: Japan – Forecast for Untapped Numbers (Number), 2022 – 2027
- Figure-09: Japan – Central Nervous System (CNS) Tumors Patients (Number), 2016 – 2021
- Figure-10: Japan – Forecast for Central Nervous System (CNS) Tumors Patients (Number), 2022 – 2027
- Figure-11: Japan – Head and Neck Cancer Patients (Number), 2016 – 2021
- Figure-12: Japan – Forecast for Head and Neck Cancer Patients (Number), 2022 – 2027
- Figure-13: Japan – Lung Cancer Patients (Number), 2016 – 2021
- Figure-14: Japan – Forecast for Lung Cancer Patients (Number), 2022 – 2027
- Figure-15: Japan – GI (Gastro-Intestinal) Cancer Patients (Number), 2016 – 2021
- Figure-16: Japan – Forecast for GI (Gastro-Intestinal) Cancer Patients (Number), 2022 – 2027
- Figure-17: Japan – Hepatocellular Carcinoma (HCC) Cancer Patients (Number), 2016 – 2021
- Figure-18: Japan – Forecast for Hepatocellular Carcinoma (HCC) Cancer Patients (Number), 2022 – 2027
- Figure-19: Japan – Pancreas Cancer Patients (Number), 2016 – 2021
- Figure-20: Japan – Forecast for Pancreas Cancer Patients (Number), 2022 – 2027
- Figure-21: Japan – Gynecologic Cancers Patients (Number), 2016 – 2021
- Figure-22: Japan – Forecast for Gynecologic Cancers Patients (Number), 2022 – 2027
- Figure-23: Japan – Prostate Cancer Patients (Number), 2016 – 2021
- Figure-24: Japan – Forecast for Prostate Cancer Patients (Number), 2022 – 2027
- Figure-25: Japan – Bone and Soft Tissue Cancer Patients (Number), 2016 – 2021
- Figure-26: Japan – Forecast for Bone and Soft Tissue Cancer Patients (Number), 2022 – 2027
- Figure-27: Japan – Others Cancer Patients (Number), 2016 – 2021
- Figure-28: Japan – Forecast for Others Cancer Patients (Number), 2022 – 2027
- Figure-29: Japan – Central Nervous System (CNS) Tumors Market (Million US$), 2016 – 2021
- Figure-30: Japan – Forecast for Central Nervous System (CNS) Tumors Market (Million US$), 2022 – 2027
- Figure-31: Japan – Head and Neck Cancer Market (Million US$), 2016 – 2021
- Figure-32: Japan – Forecast for Head and Neck Cancer Market (Million US$), 2022 – 2027
- Figure-33: Japan – Lung Cancer Market (Million US$), 2016 – 2021
- Figure-34: Japan – Forecast for Lung Cancer Market (Million US$), 2022 – 2027
- Figure-35: Japan – GI (Gastro-Intestinal) Cancer Market (Million US$), 2016 – 2021
- Figure-36: Japan – Forecast for GI (Gastro-Intestinal) Cancer Market (Million US$), 2022 – 2027
- Figure-37: Japan – Hepatocellular Carcinoma (HCC) Cancer Market (Million US$), 2016 – 2021
- Figure-38: Japan – Forecast for Hepatocellular Carcinoma (HCC) Cancer Market (Million US$), 2022 – 2027
- Figure-39: Japan – Pancreas Cancer Market (Million US$), 2016 – 2021
- Figure-40: Japan – Forecast for Pancreas Cancer Market (Million US$), 2022 – 2027
- Figure-41: Japan – Gynecologic Cancers Market (Million US$), 2016 – 2021
- Figure-42: Japan – Forecast for Gynecologic Cancers Market (Million US$), 2022 – 2027
- Figure-43: Japan – Prostate Cancer Market (Million US$), 2016 – 2021
- Figure-44: Japan – Forecast for Prostate Cancer Market (Million US$), 2022 – 2027
- Figure-45: Japan – Bone and Soft Tissue Cancer Market (Million US$), 2016 – 2021
- Figure-46: Japan – Forecast for Bone and Soft Tissue Cancer Market (Million US$), 2022 – 2027
- Figure-47: Japan – Others Cancer Market (Million US$), 2016 – 2021
- Figure-48: Japan – Forecast for Others Cancer Market (Million US$), 2022 – 2027
- Figure-49: IBA Proton Therapy – Global Revenue (Million US$), 2016 – 2021
- Figure-50: IBA Proton Therapy – Forecast for Global Revenue (Million US$), 2022 – 2027
- Figure-51: Varian Medical Systems – Global Revenue (Million US$), 2016 – 2021
- Figure-52: Varian Medical Systems – Forecast for Global Revenue (Million US$), 2022 – 2027
- Figure-53: Elekta – Global Revenue (Million US$), 2016 – 2021
- Figure-54: Elekta – Forecast for Global Revenue (Million US$), 2022 – 2027
- List Of Tables:
- Table-1: Japan – Proton Therapy Centers in Operation
- Table-2: Japan – Proton Therapy Centers in Under-Construction
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook